Site icon Alpha Edge Investing

DBS: Raffles Medical Group Ltd – Hold Target Price $1.48

3Q2023 Results Analysis: A soft quarter

What happened?

Raffles Medical’s 3Q23 performance moderated more-than-expected after delivering an exceptionally stellar year in FY2022 which forms a high base. 3Q23 PAT fell by 67% y-o-y to S$12.4m and 9% below that of 3Q2019. 9M23 PAT fell 26% y-o-y to S$72.8m, 53% of our FY2023 estimates. While Singapore core operations remain strong and profitable, discontinuation of COVID-19 activities, cost inflation and gestation losses from China continue to weigh down on performance and profitability. In addition, RafflesHealthInsurance (RHI) registered higher claims in 3Q23. No further financial / operational numbers were disclosed for now as this is a business update. 

Our View

Operationally, Raffles Medical’s contract to manage the Transitional Care Facilities (TCF) at Expo has been extended to Feb 2025. Management has highlighted that it will right-size and rationalise its China operations to achieve better operating efficiencies. We currently have a HOLD rating; TP of S$1.48. Given the exceptionally strong earnings posted in FY22, 9M23 earnings appears to have normalised, as per our expectations previously. Nevertheless, we remain long-term positive on Raffles Medical, led by the long-term positive trend of the healthcare industry and potential ramp-up of its China hospitals as it reaches stabilisation and breakeven in the medium term. 

More details after the briefing. 

Exit mobile version